Drugs in ATC Class C01D

Up to Top Level ATC Classes

Up to C - Cardiovascular system

Up to C01 - CARDIAC THERAPY

Subclasses in ATC: C01D - VASODILATORS USED IN CARDIAC DISEASES

C01DA - Organic nitrates

C01DX - Other vasodilators used in cardiac diseases

Market Dynamics and Patent Landscape for ATC Class C01D (Vasodilators Used in Cardiac Diseases): What Patents Protect, When Exclusivity Ends, and Where Generic and Challenge Risk Concentrates

Last updated: June 20, 2026

ATC C01D vasodilators used in cardiac diseases spans multiple drug actives and dosage forms, with patent protection split across (1) originator small molecules, (2) fixed-dose combinations, (3) sustained-release formulations, (4) second-generation prodrugs, and (5) nitric-oxide pathway agents. Across the class, the highest near-term generic and biosimilar-replacement risk is concentrated in: (a) older oral generics transitioning from primary composition patents to formulation and polymorph IP, and (b) depot or controlled-release products where protracted formulation estates delay true “drop-in” entry. Litigation and Orange Book-style regulatory listings (for US) determine the timing of Para IV entry opportunities and settlement-driven “authorized” launch dates.

Because ATC C01D is a therapeutic class rather than a single product, this market requires asset-by-asset mapping of: active ingredient, dosage form, route (oral, sublingual, IV, transdermal where applicable), and the jurisdictional IP stack (US, EP, JP). Without that product-to-product mapping, any attempt to provide exact patent numbers, filing dates, expiration dates, and Orange Book status would be incomplete and not fit a litigation- or licensing-grade analysis.

Which vasodilators fall under ATC Class C01D and how does that shape patent coverage?

Featured snippet: C01D covers cardiology vasodilators whose IP estates typically split between active ingredient composition, use (method-of-use), and formulation (controlled release, salt forms, polymorphs, and delivery systems).

Key subcategories driving different patent regimes

1) Nitrates and nitric oxide donors

• Typical patent structure: composition (and salts/solvates), manufacturing/process patents, and formulation patents tied to sustained release and dosing regimens.
• Patent risk timing: often driven by older composition patent expiries, then prolonged by formulation and process claims.

2) Direct vasodilators and K+ channel modulators used in cardiac disease

• Patent structure: composition and selectivity claims, plus formulation for oral bioavailability control.
• Patent risk timing: depends on whether subsequent generations or improved PK/PD variants exist.

3) Calcium channel blockers overlap issue (taxonomy mismatch)

• Many calcium channel blocker vasodilators are categorized elsewhere in ATC systems; where C01D includes specific agents, their patents behave like standard cardiovascular small-molecule portfolios with strong formulation control for long-acting profiles.
• Market impact: competitors frequently target release kinetics and food-effect stability via formulation work.

How the class taxonomy changes market dynamics

• Broad class labeling means prescribers and payers often drive demand by symptom control and dosing convenience, which tends to favor long-acting and adherence-optimized formulations.
• Patent barriers shift from active ingredient to dosing form IP once the primary molecule ages.

What patents protect ATC C01D vasodilators used in cardiac diseases?

Featured snippet: Patent estates for C01D agents typically include composition-of-matter, formulation (including controlled release), and method-of-use claims; process and crystal/polymorph patents can be decisive for generics.

Patent layers that matter for enforcement and generic “design-around”

1. Composition-of-matter

• Covers the active ingredient and sometimes salts/solvates and prodrug variants.
• Strongest against “copy-and-same” generics, but expires first.

2. Formulation and release technology

• Controlled-release matrices, osmotic pumps, multilayer tablets, enteric coatings, and optimized dissolution profiles.
• Frequently extended by later filings on specific release curves, excipient systems, and stability.

3. Polymorph/crystal form patents

• Claim specific crystal forms and solid-state properties.
• This is a common barrier in oral vasodilators when existing generics use different solid-state forms.

4. Method-of-use and dosing regimens

• Claims tied to specific cardiovascular indications, patient subgroups, or dosing schedules.
• These claims can block “label-to-practice” even if composition patents expire, depending on enforcement and claim scope.

5. Manufacturing/process

• Solvent selection, drying conditions, particle-size control, and scale-up steps.
• Used to complicate generic manufacture and to support injunction leverage.

What this implies for licensing strategy

• Licensing deals in C01D often target formulation estates (controlled-release IP) rather than the active molecule, especially where multiple generics already exist for the composition.
• Value transfers toward technologies that protect release characteristics and bioequivalence defensibility.

When does exclusivity end for C01D vasodilators, and what does that mean for generic launch timing?

Featured snippet: Generic entry timing is governed by the last-to-expire patent type, not the first-to-expire composition claim, with formulation and solid-state patents often delaying “true” market replacement.

Typical exclusivity and patent-expiration sequencing

• Composition patent expiry usually opens the door for basic generics.
• Formulation/polymorph/process patents then determine whether generic products are easier or harder to launch as “AB-rated” alternatives.
• Settlement agreements can move entry by months to years even when filing dates suggest earlier FDA approval.

Generic launch scenarios that dominate in C01D

1. Early generic by composition expiry

• Generic enters once the composition is free of enforceable claims.
• Remaining risk is formulation equivalence and solid-state barriers.

2. Staggered entry by formulation/polymorph

• Competitors launch “clean” formulations first.
• Later entry requires overcoming controlled-release or specific crystal form claims.

3. Authorized generic or brand continuation

• Settlements can preserve market share via licensing or brand-sponsor authorized products.
• This is especially likely where formulation IP creates a manufacturing or product design constraint.

What is the Orange Book status of C01D vasodilators, and how does it affect Para IV strategy?

Featured snippet: Orange Book listings in the US map to listed patents; Para IV challenges succeed when the challenger attacks patents that are “listed for” the marketed product and are not protected by viable enforcement or settlement barriers.

How Orange Book listings translate into legal leverage

• If the marketed product has multiple listed patents, Para IV often targets the “dominant” patents: formulation, polymorph, and method-of-use.
• If patents are not listed, challengers may still face injunction risk depending on claim relationships and jurisdictional enforcement.

How to read the landscape (market behavior, not single-product claims)

• Where an originator lists extensive formulation patents, generic entrants typically face higher litigation spend and delayed launch.
• Where the originator’s listed patents are thin beyond composition, challengers tend to file earlier and settle closer to statutory timelines.

Which patent estate components most often block generic substitution in C01D?

Featured snippet: Controlled-release formulation patents and solid-state polymorph/crystal form patents most often block practical generic substitution in C01D once composition patents expire.

Controlled-release and solid-state as the recurring choke points

• Vasodilators used for chronic cardiac indications rely on stable symptom control. That creates a high commercial premium on matching pharmacokinetics and dissolution.
• Controlled-release and solid-state patents enable originators to claim that generics cannot replicate release and stability without infringement.

Manufacturing/process patents as secondary blockers

• Even with a compliant formulation target, process constraints can be litigated if claims cover specific manufacturing steps.
• For smaller generic manufacturers, process complexity raises the cost to comply and increases schedule risk.

What patent litigation affects C01D vasodilators and how does it move entry dates?

Featured snippet: Litigation affects C01D entry mainly through (a) automatic stay mechanics in the US framework and (b) settlement-driven launch dates for competing generics and authorized products.

Litigation patterns across cardiovascular formulations

• Originators commonly sue on: composition listed patents, controlled-release claims, and method-of-use/dosing regimen claims tied to label.
• Generic challengers commonly contest: claim construction and invalidity based on prior art, obviousness, and lack of enablement.

Settlement-driven market outcomes

• Settlements frequently trade early entry for market certainty by granting a noninfringing “design” or licensing a delayed launch.
• This is common when multiple listed patents create a high probability of defeat at early stage.

How do key C01D drugs compare in patent strength, formulation risk, and generic competition?

Featured snippet: Patent strength in C01D is product-specific; the strongest estates are typically long-acting or solid-state technology-heavy formulations with multiple late-filed formulation and polymorph patents.

Comparative factors that change the “winner” among challengers

• Number of listed patents per marketed strength/dosage form.
• Presence of polymorph/crystal form restrictions.
• Controlled-release technology scope (matrix vs coating vs multilayer vs osmotic).
• Method-of-use claim overlap with label and standard dosing practice.
• How many generic candidates have already launched (price pressure) versus how many are blocked by ongoing litigation.

What generic entry risks exist for C01D vasodilators by dosage form (IR vs SR/ER vs IV)?

Featured snippet: Risk concentrates in sustained-release/controlled-release and solid-state-defined products; immediate-release generics face lower formulation IP friction.

Dosage-form risk profile

• Immediate-release oral: mostly composition and basic formulation; lower likelihood of polymorph-specific barriers after early years.
• Sustained-release/extended-release: higher risk due to release kinetics claims, dissolution targets, and stability.
• IV preparations: manufacturing process and sterile formulation can be decisive.
• Sublingual/transdermal where applicable: delivery-system and stability patents can be more prominent.

Which companies are challenging C01D patents and where does competitive pressure concentrate?

Featured snippet: Generic challengers concentrate on products with high market share and dense Orange Book listings that provide multiple targets for Para IV filings, often seeking settlement leverage rather than full trial outcomes.

Competitive behavior by market segment

• Large generics file for high-liquidity products with multiple listed patents.
• Smaller generics target lower-risk entries, often by selecting product presentations where listed patent counts are lower or where prior art is stronger.
• Brand sponsors defend via cross-assertion of formulation and method-of-use claims.

What revenue exposure do patent expiries create across C01D?

Featured snippet: Revenue exposure is a function of the product’s share, the presence of multiple listed patents, and the number of alternative dosing forms already available; formulation-heavy products can extend revenue well after composition expiry.

Practical drivers of revenue at risk

• Degree of category switching: if the class provides substitutes (different nitrates/vasodilators with similar symptom relief), price erosion can occur quickly after barriers fall.
• Tender and hospital formularies: these can accelerate substitution after an injunction lifts.
• Payer dynamics: coinsurance and prior authorization can slow uptake even when generics launch.

Key Takeaways

• ATC C01D is a multi-asset class; patent landscape and generic timing are driven by product-specific estates, not the class label.
• In C01D, the most persistent generic substitution barriers usually come from controlled-release formulation IP and solid-state (polymorph/crystal form) patents.
• Orange Book-listed patents determine Para IV leverage in the US; the last-to-expire listed patents often govern entry more than early composition expiries.
• Litigation and settlement frequently shift launch dates from “statutory expectation” to calendar-based deal outcomes.
• Commercial risk concentrates in sustained-release, solid-state-defined presentations with dense patent listing sets.

FAQs

1. How do formulation and polymorph patents change bioequivalence and “AB-rating” outcomes for C01D generics?
2. What factors determine whether a Para IV challenge targets method-of-use versus formulation patents in US C01D cases?
3. Do process patents for sterile or controlled-release vasodilators create higher injunction risk than composition patents?
4. How do settlement agreements in cardiovascular patent cases typically shift generic entry dates for long-acting products?
5. What product presentation details (strength, release profile, solid-state form) matter most when evaluating C01D patent risk for a launch plan?

References

1. European Medicines Agency (EMA). European public assessment reports and product information (site navigation for ATC C01D assignments).
2. Food and Drug Administration (FDA). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
3. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC classification (C01D).